Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcus capitis E12 is a strain of coagulase-negative, Gram-positive bacteria isolated from healthy human skin. It exhibits potent antimicrobial activity against Cutibacterium acnes (C. acnes), the bacterium implicated in acne vulgaris. This strain produces four distinct phenol-soluble modulins (PSMs) that act synergistically to inhibit C. acnes growth. It is being explored as a biotherapeutic approach for treating acne vulgaris.
Secretion of phenol-soluble modulins (PSMs) that selectively kill Cutibacterium acnes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcus capitis E12 (S. capitis E12).